Li Chuanming, Yu Fan, Xu Wanli
Department of Anorectal Surgery, Wuhan No. 8 Hospital (Wuhan Anorectal Hospital), Wuhan, Hubei 430000, P.R. China.
Department of Gastroenterology, Wuhan No. 8 Hospital (Wuhan Anorectal Hospital), Wuhan, Hubei 430000, P.R. China.
Oncol Lett. 2023 Jun 15;26(2):329. doi: 10.3892/ol.2023.13915. eCollection 2023 Aug.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) modulates colorectal cancer (CRC) malignant behaviors and tumor immune escape. The present study aimed to explore the association of MALT1 with treatment response and survival time among patients with metastatic CRC (mCRC) after programmed cell death protein-1 (PD-1) inhibitor-based treatment. MALT1 from the blood samples of 75 patients with unresectable mCRC receiving PD-1 inhibitor-based treatment at baseline and after 2-cycle treatment, as well as 20 healthy controls (HCs), was detected by reverse transcription-quantitative PCR. In the patients with mCRC, the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were calculated. MALT1 expression was elevated in patients with mCRC compared with that in HCs (P<0.001). In patients with mCRC, MALT1 expression was positively correlated with multiple (vs. single) metastasis (P=0.032) and peritoneum metastasis (P=0.029). MALT1 levels before treatment were decreased in ORR patients vs. non-ORR patients (P=0.043) and in DCR patients vs. non-DCR patients (P=0.007). Additionally, MALT1 expression was reduced after treatment compared with that before treatment (P<0.001). Meanwhile, MALT1 expression after treatment was notably decreased in ORR patients vs. non-ORR patients (P<0.001) and in DCR patients vs. non-DCR patients (P<0.001). Furthermore, a low MALT1 level before treatment was associated with longer PFS (P=0.030) and OS (P=0.025) times. Decreased MALT1 expression after treatment and a decline in MALT1 expression of >30% after treatment (ratio to MALT1 before treatment) (both P≤0.001) presented more significant associations with prolonged PFS and OS times. In conclusion, early low levels of blood MALT1 during therapy may predict an improved response to PD-1 inhibitor-based treatment and survival time in patients with mCRC.
黏膜相关淋巴组织淋巴瘤易位蛋白1（MALT1）调节结直肠癌（CRC）的恶性行为和肿瘤免疫逃逸。本研究旨在探讨MALT1与接受程序性细胞死亡蛋白1（PD-1）抑制剂治疗后的转移性结直肠癌（mCRC）患者的治疗反应和生存时间之间的关联。通过逆转录定量PCR检测了75例在基线和2周期治疗后接受基于PD-1抑制剂治疗的不可切除mCRC患者以及20例健康对照（HC）血液样本中的MALT1。计算了mCRC患者的客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）和总生存期（OS）。与HC相比，mCRC患者的MALT1表达升高（P<0.001）。在mCRC患者中，MALT1表达与多发（与单发）转移（P=0.032）和腹膜转移（P=0.029）呈正相关。ORR患者与非ORR患者相比（P=0.043）以及DCR患者与非DCR患者相比（P=0.007），治疗前MALT1水平降低。此外，与治疗前相比，治疗后MALT1表达降低（P<0.001）。同时，ORR患者与非ORR患者相比（P<0.001）以及DCR患者与非DCR患者相比（P<0.001），治疗后MALT1表达显著降低。此外，治疗前低水平的MALT1与更长的PFS（P=0.030）和OS（P=0.025）时间相关。治疗后MALT1表达降低以及治疗后MALT1表达下降>30%（与治疗前MALT1的比值）（均P≤0.001）与延长的PFS和OS时间呈现更显著的关联。总之，治疗期间早期血液中低水平的MALT1可能预测mCRC患者对基于PD-1抑制剂治疗的反应改善和生存时间延长。
